|1.||Xia, Ying: 7 articles (05/2014 - 06/2002)|
|2.||Chao, Dongman: 3 articles (05/2014 - 02/2007)|
|3.||Bazzy-Asaad, Alia: 3 articles (07/2007 - 02/2007)|
|4.||Suzuki, T: 3 articles (12/2001 - 04/2000)|
|5.||Suzuki, Tsutomu: 2 articles (07/2015 - 03/2014)|
|6.||Barrot, Michel: 2 articles (08/2010 - 11/2008)|
|7.||Yalcin, Ipek: 2 articles (08/2010 - 11/2008)|
|8.||Zhou, Fei: 2 articles (08/2008 - 06/2008)|
|9.||Yang, Ru: 2 articles (08/2008 - 06/2008)|
|10.||Zhao, Peng: 2 articles (05/2007 - 06/2002)|
08/25/2009 - "In contrast, CTAP and Naltrindole did not change Tb during hypoxia but caused a longer latency for the return of Tb to the normoxic values just after low O2 exposure. "
11/01/2008 - "We examined the effect of DOR blockade with naltrindole (1-10 micromol l(-1)) on E(m), NMDAR activity and [Ca(2+)](c) homeostasis in turtle cortical neurons during normoxia and the transition to anoxia. "
05/29/2007 - "Along with the injury, either by hypoxia or naltrindole, phosphorylated p38 increased in a major way, while phosphorylated ERK and JNK had no significant change or slightly decreased. "
05/29/2007 - "DOR inhibition with naltrindole (10 microM) led to significant injury in normoxic neurons after 24 h of treatment and exacerbated hypoxia-induced injury. "
01/01/2002 - "Naltrindole reversed residual hypoxia, however, not hypercarbia or amplitude reduction of the evoked potential. "
|2.||Hypoglycemia (Reactive Hypoglycemia)
07/02/2007 - "In rats with inflammation-induced pain, (-)-NIH 11082 produced antihyperalgesic effects that were attenuated by naltrindole. "
01/30/1995 - "For this reason, we have examined the effects of the delta-opioid antagonist naltrindole (NTI) on the modulation of morphine antinociceptive potency resulting from carrageenan-induced inflammation. "
01/30/1995 - "The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw inflammation is blocked by naltrindole, a selective delta-opioid antagonist."
01/01/1999 - "In the present study, to elucidate the mechanism of this attenuation, the effects of pretreatment with delta- and kappa-opioid receptor antagonists, naltrindole (NTI) and nor-binaltorphimine (nor-BNI), on the development of the morphine-induced place preference under inflammation were examined in rats. "
12/01/2001 - "Therefore, to elucidate the mechanism of this attenuation, the effects of pretreatment with kappa- and delta-opioid receptor antagonists, nor-binaltorphimine (nor-BNI) and naltrindole (NTI), on the development of the morphine-induced place preference under inflammation were examined. "
08/15/1994 - "The NMR conformational study in a dimethylsulfoxide/water cryoprotective mixture at low temperature shows diagnostic side-chain--side-chain NOEs in the spectra of all [L-Tic2]peptides and hints that the 90 degrees arrangement of the the two aromatic rings found in the cis-Tyr-L-Tic moiety, typical of N-methyl naltrindole and other delta-selective opiate antagonists, is responsible for the antagonist activity of all these peptides."
10/01/2001 - "In contrast, total receptor protein and sites labeled by neutral antagonists [(3)H]naltrindole and [(3)H]Tyr-D-Tic-Phe-Phe-OH remained unchanged. "
07/01/1997 - "Cyclo-[Tyr(Me)2-Tic-], the diketopiperazine of 2,6-dimethyltyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, is a partially rigid opioid antagonist; its pA2 (5.8) is one smaller than that of N,N-bisallyl-enkephalin but it has a very high binding affinity (10 nM) and has a delta selectivity (66 with respect to the binding to mu receptors) higher than that of naltrindole. "
04/04/1996 - "The minimum effective doses of naltrindole and naltriben were 0.1 mg/kg. Doses of 0.1-1.0 mg/kg produced few, if any, somatic signs of withdrawal whereas higher doses of these antagonists only produced diarrhea and wet-dog shakes. "
03/01/1995 - "The aim of the study was to evaluate the effects of centrally and peripherally acting opioid antagonists such as naloxone (NX), naloxone methiodide, (+)-naloxone [(+)NX], (-)-a-5,9-diethyl-2'-hydroxy-2 (3-furylmethyl)-6,7-benzomorphan and naltrindole on gastrointestinal (GI) transit in mice with diarrhea associated with intestinal inflammation. "
08/10/1993 - "Treatment with naltrindole (0.1, 1, or 10 nmol/5 microliters per rat) significantly blocked naloxone-, a nonspecific antagonist, precipitated butorphanol withdrawal behaviors (escape behavior, teeth-chattering, wet shakes, forepaw tremors, ptosis, diarrhea, body weight loss, and hypothermia) at all doses tested, and decreased ejaculation at 0.1 nmol in butorphanol-infused rats. "
|1.||Opioid Receptors (Opioid Receptor)
|4.||Narcotic Antagonists (Opioid Antagonists)
|8.||Morphine (MS Contin)
|10.||kappa Opioid Receptors (kappa Opioid Receptor)
|3.||Heterologous Transplantation (Xenotransplantation)